Interim Report – Q1-Q3, 2021

Interim Report - Q1-Q3, 2021

November 2021

2

Forward-looking statements

Certain information set forth and given in this presentation contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-

looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates' business, projects and joint ventures; (iii) execution of ViroGates' vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates' projects; (v) completion of ViroGates' projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates' current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of

ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Contents

Summary4

Management review

8

Financial statements

13

Statement by the Board and 23

Executive Management

3

On 11 November 2021, the Board of Directors has accepted the interim report for the third quarter of 2021 (the period 1 July - 30 September 2021) for ViroGates A/S.

The interim report is unaudited.

4

Contents

Summary	4
Management review	8

Financial statements

13

Statement by the Board and	23
Executive Management

5

Revenue increased by 66% in Q1-Q3, 2021, compared to last year - Q3

revenue was lower than recent quarters due to hospital vacation periods

Financial results in Q1-Q3, 2021

(Q1-Q3, 2020 results in brackets)

• Revenue increased by 66% to TDKK 5,063 (TDKK 3,055)
• Operating expenses increased by 8% to TDKK -19,354 (TDKK -17,862)
• Operating loss decreased by -3% to TDKK -14,455 (TDKK -14,974)
• Net loss decreased by -5% to TDKK -13,641 (TDKK -14,293)
• Cash and cash equivalents at the end of the period amounted to TDKK 17,475 (TDKK 38,032)

"We continue to see revenue growth compared to the same period last year. The revenue in Q3 was lower than previous quarters due to the seasonal effect from the summer vacation and fewer COVID-19-related tests due to fewer patients. Although emergency department sales activities have been hindered by the COVID-19 pandemic, we still expect to become cash flow positive with the existing cash at hand."

Mark Christian Hvidberg da Silva, CFO	Mark da Silva

TDKK+66%

Revenue 3,055 5,063

Operating		-3%
loss
		-14,455
-14,974
			-54%
38,032	17,475
Cash
balance
Q1-Q3, 2020	Q1-Q3, 2021